Compounded Tirzepatide Clinics in District of Columbia

Compounded tirzepatide is not FDA-approved. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality. Across 2025–2026 the FDA restricted compounding of these medicines to documented medical need through state-licensed 503A / 503B pharmacies, and has warned about fraudulent and counterfeit compounded GLP-1 products.

FDA references: human drug compounding policy (FDA, April 2026 update) · warning on fraudulent compounded GLP-1 products (FDA, June 2026). This is factual information, not medical advice — confirm current legality and your own eligibility with a licensed clinician.